Claims
- 1. A pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HT1 agonist, characterized in that the composition is a solid fast-dispersing dosage form which disintegrates within 1 to 10 seconds of being placed in the oral cavity, said solid fast-dispersing dosage form comprising a network of the active ingredient and a water-soluble or water-dispersible carrier which is inert toward the active ingredient, the network having been obtained by subliming solvent from a composition in the solid state.
- 2. A composition according to claim 1 in which the composition is formulated to promote pre-gastric absorption of said 5-HT1 agonist.
- 3. A composition according to claim 1 in which the composition is formulated to promote absorption of said 5-HT1 agonist through the buccal, sublingual, pharyngeal and/or esophageal mucous membrane.
- 4. A composition according to claim 1 in which the composition is formulated to promote absorption of said 5-HT1 agonist through the stomach mucous membrane.
- 5. A composition according to claim 1 in which the 5-HT1 agonist is selected from buspirone, gepirone, ipsapirone, zalospirone, umespirone, alnespirone, enilospirone, WY-48723, SUN-8399, tandospirone, flesinoxan, lesopitron, ebalzotan, adatanserin, LY-228729, F-8910-RS, U-93385, SL-87.0765, FG-5893, S-14506, EMD-56551, HT-90B, F-92502-CN, E-4414, MKC-242, F-12439, BIMT-17, LY-39, SL-88.0338, SR-57746A, LY-175644, A-74283, Bay-r-1531, CGS-12066B, CGP-50281, WAY-100012, 3a,4,4a,6a,7,7a-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-[piperazinyl]butyl]-4,7-ethenocyclobuta[f]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide, cis-7-chloro-10-methoxy-5a 10b-dihydro-3N-n-propyl-6H-indeno[ 1,2-d]azepine, 1-cyclohexyl-3-[4-[4-(2,3-dihydro-2,2-dimethylbenzofuran-7-yl)-1-piperazinyl]-1-butyl]-2-imidazolidinone,1-[3-amino-2H-1-benzopyran-2-one-8-yl]piperazine, oxaflozane, RU-5031, CP-93129, naratriptan, avitriptan, rizatriptan, L-694247, IS-159, almotriptan, zolmitriptan, sumatriptan, eletriptan, VML-251, L-0076, ALX-0625, CP-122288, VS-395, L-747201, LY-334370 and salts thereof.
- 6. A composition according to claim 1 in which the 5-HT1 agonist is a 5-HT1A agonist.
- 7. A composition according to claim 6 in which the 5-HT1 agonist is selected from buspirone, gepirone, ipsapirone, zalospirone, umespirone, alnespirone, enilospirone, WY-48723, SUN-8399, tandospirone and salts thereof.
- 8. A composition according to claim 7 in which the 5-HT1 agonist is buspirone or a salt thereof.
- 9. A composition according to claim 1 in which the active ingredient is present in an amount of from 0.5 to 30% by weight of the composition.
- 10. A composition according to claim 1 in which the active ingredient is present in an amount of 0.25 to 50 mg.
- 11. A pharmaceutical composition for oral administration comprising a carrier, and buspirone as an active ingredient, characterized in that the composition is in the form of a solid fast-dispersing dosage form comprising a network of buspirone and a water-soluble or water-dispersible carrier which is inert towards buspirone, the network having been obtained by subliming solvent from a composition in the solid state, that composition comprising buspirone and a solution of the carrier in a solvent, wherein said solid fast-dispersing dosage form disintegrates within 1 to 10 seconds of being placed in the oral cavity.
- 12. A composition as defined in claim 1 for use in the treatment of anxiety.
- 13. Use of a composition as defined in claim 1 for the manufacture of a medicament for the treatment of depression.
- 14. Use of a composition as defined in claim 1 for the manufacture of a medicament for the treatment of Attention Deficit Disorder With or Without Hyperactivity.
- 15. Use of a composition as defined in claim 1 for the manufacture of a medicament for the treatment of panic disorders.
- 16. Use of a composition as defined in claim 1 for the manufacture of a medicament for use as a memory enhancer.
- 17. Use of a composition as defined in claim 1 for the manufacture of a medicament for the palliative treatment of anxiety neurosis.
- 18. Use of a composition as defined in claim 1 for the manufacture of a medicament for the treatment and/or prophylaxis of incontinence disorders.
- 19. Use of a composition as defined in claim 1 for the manufacture of a medicament for inducing immunosuppression and/or treating immune disorders.
- 20. Use of a composition as defined in claim 1 for the manufacture of a medicament for the treatment of sleep apnea and/or related respiratory disorders.
- 21. Use of a composition as defined in claim 1 for the manufacture of a medicament for the treatment for substance addiction.
- 22. Use of a composition as defined in claim 1 for the manufacture of a medicament for the treatment of alcohol abuse.
- 23. Use of a composition as defined in claim 1 for the manufacture of a medicament for the alleviation of extrapyramidal motor disorders.
- 24. Use of a fast-dispersing dosage form designed to release active ingredient within 1 to 60 seconds of being placed in the oral cavity to deliver a 5-HT1 agonist.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9706089.1 |
Mar 1997 |
GB |
|
RELATED APPLICATION DATA
[0001] This Application is a continuation-in-part of U.S. patent application Ser. No. 09/408,595; filed Sep. 23, 1999 which is a Continuation of International Application No. PCT/GB98/00885, filed Mar. 24, 1998 (claiming priority from British Application No. 9706089.1, filed Mar. 24, 1997), now pending, which are hereby incorporated by reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/GB98/00885 |
Mar 1998 |
US |
Child |
09408595 |
Sep 1999 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09408595 |
Sep 1999 |
US |
Child |
10375560 |
Feb 2003 |
US |